Feng Zhang and colleagues report that the engineering of a compact RNA-guided nuclease, NovaIscB, derived from the OMEGA system enables efficient and...
Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...
Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...
Researchers have developed a compact, all-in-one CRISPR-dCas9-based repressor platform delivered via AAV, effectively silencing gene expression...
In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...
By targeting a highly conserved master controller sequence, Tune Therapeutics' lead candidate TUNE-401 can epigenetically silence all forms of the...
Gene-editing systems, especially CRISPR-Cas9, have revolutionised genome editing, offering potential cures for genetic disorders, cancers, and other...
